MaxCyte, Inc. Files 8-K on Financials

Ticker: MXCT · Form: 8-K · Filed: May 7, 2024 · CIK: 1287098

Sentiment: neutral

Topics: financial-condition, results-of-operations, sec-filing

Related Tickers: MXCT

TL;DR

MaxCyte filed an 8-K, check it for financial updates.

AI Summary

MaxCyte, Inc. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosures and financial statements and exhibits. Specific financial figures or operational details were not provided in the initial header information.

Why It Matters

This filing provides investors with updated information on MaxCyte's financial performance and operational status, which can influence investment decisions.

Risk Assessment

Risk Level: low — The filing is a standard 8-K reporting financial condition and results of operations, not indicating immediate or significant new risks.

Key Players & Entities

FAQ

What specific financial results are being reported by MaxCyte, Inc. in this 8-K?

The provided header information for the 8-K filing indicates it pertains to 'Results of Operations and Financial Condition' but does not detail specific financial figures.

What is the primary purpose of this 8-K filing for MaxCyte, Inc.?

The primary purpose is to report on the company's results of operations and financial condition, along with Regulation FD disclosures and financial statements and exhibits.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on May 7, 2024.

Where are MaxCyte, Inc.'s principal executive offices located?

MaxCyte, Inc.'s principal executive offices are located at 9713 Key West Avenue, Suite 400, Rockville, Maryland 20850.

What standard industrial classification does MaxCyte, Inc. fall under?

MaxCyte, Inc. falls under the standard industrial classification of SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731].

Filing Stats: 711 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-05-07 16:14:24

Key Financial Figures

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On May 7, 2024, MaxCyte, Inc. (the " Company ") issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act ") or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On May 7, 2024, the Company posted an updated corporate presentation, which the Company may use from time to time in communications or conferences, to its website at https://investors.maxcyte.com. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.2 hereto, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language in any filings, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release, dated May 7, 2024 99.2 Corporate Presentation, dated May 2024 104 Cover Page Interactive Data (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MaxCyte, Inc. Dated: May 7, 2024 By: /s/ Douglas Swirsky Douglas Swirsky Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing